Cardiff and Vale University Health Board has selected Nervecentre to provide its electronic prescribing and medicines administration solution, to support its digital transformation aspirations.
The cloud-based EPMA software will be deployed across the health board’s nine hospitals, as it looks to digital technology to help drive clinical service transformation. The implementation will introduce a digital-first approach to medicines management, and revolutionise how nearly 7,000 clinicians prescribe medications for their patients.
According to Nervecentre, the EPMA gives clinicians better visibility of medicine prescribing and administration and speeds up response times which helps release more time for care.
David Thomas, director of digital and health intelligence at Cardiff and Vale, said “Digital transformation is a priority for Cardiff and Vale UHB to shape the way we deliver services in the future and improve quality and patient care.
“We are looking forward to working with Nervecentre to implement and deliver the new EPMA system across our workforce, which will revolutionise the way we do things. The new system will be a positive culture change for the health board and increase patient safety. We will be working closely with staff groups over the coming months to build the system to meet our needs and provide training which will make a huge difference to the way we prescribe and administer medicines.”
The modern cloud platform selected by Cardiff and Vale has the potential to enable collaboration and joined-up working with neighbouring health boards. The platform is also designed to enable rapid development and implementation of functional changes and support agile service transformation and zero planned downtime for updates.
In addition, it offers real-time data that can be captured and accessed on mobile devices, which will help ensure hospitals are safer and can run more efficiently.
In 2022, Nervecentre was awarded a place on the all-Wales EPMA framework – one of only three companies to achieve this. Cardiff and Vale became the first health board to select its preferred EPMA system, following a rigorous and clinically-led competitive tender process.
Nervecentre CEO, Paul Volkaerts said: “I am very excited for Nervecentre to win its first contract in Wales and look forward to working closely with Cardiff and Vale UHB to digitise its prescribing. I am especially pleased to be working with an NHS organisation that is embracing the cloud technology we use daily in our personal lives, which will provide them with the agility and adaptability that is necessary for successful clinical service transformation at pace.”